XOMA Competitors
| XOMA Stock | USD 23.65 1.21 4.87% |
XOMA Corp vs DiaMedica Therapeutics Correlation
Very good diversification
The correlation between XOMA Corp and DMAC is -0.5 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding XOMA Corp and DMAC in the same portfolio, assuming nothing else is changed.
Moving together with XOMA Stock
Moving against XOMA Stock
| 0.81 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.72 | DSGN | Design Therapeutics | PairCorr |
| 0.65 | ENGN | enGene Holdings Common | PairCorr |
| 0.56 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.36 | 63E | ONWARD MEDICAL BV | PairCorr |
XOMA Corp Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between XOMA Corp and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of XOMA and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of XOMA Corp does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between XOMA Stock performing well and XOMA Corp Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze XOMA Corp's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GALT | 4.43 | (0.89) | 0.00 | 2.91 | 0.00 | 8.89 | 39.42 | |||
| IMAB | 4.25 | 0.54 | 0.06 | (0.22) | 4.63 | 10.53 | 33.43 | |||
| BNTC | 3.26 | (0.45) | 0.00 | (0.21) | 0.00 | 5.86 | 24.40 | |||
| RCKT | 2.90 | (0.11) | (0.02) | 0.01 | 3.23 | 8.04 | 19.80 | |||
| SLDB | 3.51 | 0.64 | 0.18 | 0.51 | 3.24 | 11.36 | 21.63 | |||
| QSI | 3.47 | (1.02) | 0.00 | (0.22) | 0.00 | 7.09 | 18.33 | |||
| DSGN | 3.43 | 0.80 | 0.20 | 1.31 | 3.49 | 9.28 | 18.90 | |||
| AURA | 2.50 | (0.09) | (0.01) | 0.04 | 2.81 | 5.00 | 18.08 | |||
| AUTL | 3.95 | (0.02) | 0.00 | (0.17) | 0.00 | 10.45 | 30.76 | |||
| DMAC | 3.52 | 0.20 | 0.06 | 0.18 | 4.43 | 7.96 | 24.12 |
Cross Equities Net Income Analysis
Compare XOMA Corp and related stocks such as Galectin Therapeutics, IMAB Old, and Benitec Biopharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GALT | (190 K) | (10.9 M) | (9.7 M) | (12.1 M) | (15.8 M) | (20 M) | (21.4 M) | (16.2 M) | (13.9 M) | (13.3 M) | (23.5 M) | (30.5 M) | (38.8 M) | (41.1 M) | (47 M) | (42.3 M) | (40.2 M) |
| BNTC | (6.4 M) | (6.4 M) | (6.4 M) | (10.8 M) | (8.8 M) | (18.5 M) | (4.4 M) | (8.6 M) | 2.9 M | (8.3 M) | (13.9 M) | (18.2 M) | (19.6 M) | (21.8 M) | (37.9 M) | (34.1 M) | (32.4 M) |
| RCKT | (6.1 M) | (6.1 M) | (6.1 M) | (7.6 M) | (9.5 M) | (68 M) | (42.9 M) | (29.5 M) | (74.5 M) | (83.2 M) | (146.7 M) | (169.1 M) | (221.9 M) | (245.6 M) | (258.7 M) | (232.9 M) | (221.2 M) |
| SLDB | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (21.5 M) | (52.1 M) | (74.8 M) | (117.2 M) | (88.3 M) | (72.2 M) | (86 M) | (96 M) | (124.7 M) | (112.2 M) | (117.8 M) |
| QSI | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (36.6 M) | (95 M) | (132.4 M) | (96 M) | (101 M) | (90.9 M) | (95.5 M) |
| DSGN | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (8.3 M) | (35.5 M) | (58.6 M) | (66.9 M) | (49.6 M) | (44.6 M) | (46.9 M) |
| AURA | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (22.2 M) | (35.3 M) | (58.8 M) | (76.4 M) | (86.9 M) | (78.2 M) | (82.1 M) |
| AUTL | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (7.5 M) | (12.6 M) | (19.7 M) | (31.1 M) | (123.8 M) | (142.1 M) | (142.1 M) | (148.8 M) | (208.4 M) | (220.7 M) | (198.6 M) | (188.7 M) |
| DMAC | (640 K) | (6.6 M) | (10.1 M) | (7.4 M) | (4.8 M) | (1.4 M) | (2.2 M) | (4.3 M) | (5.7 M) | (10.6 M) | (12.3 M) | (13.6 M) | (13.7 M) | (19.4 M) | (24.4 M) | (22 M) | (20.9 M) |
XOMA Corp and related stocks such as Galectin Therapeutics, IMAB Old, and Benitec Biopharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in XOMA Corp financial statement analysis. It represents the amount of money remaining after all of XOMA Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.XOMA Corp Competitive Analysis
The better you understand XOMA Corp competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, XOMA Corp's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across XOMA Corp's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
XOMA Corp Competition Performance Charts
Five steps to successful analysis of XOMA Corp Competition
XOMA Corp's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by XOMA Corp in relation to its competition. XOMA Corp's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of XOMA Corp in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact XOMA Corp's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to XOMA Corp, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your XOMA Corp position
In addition to having XOMA Corp in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Health Care ETFs Thematic Idea Now
Health Care ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Health Care ETFs theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Care ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out XOMA Corp Correlation with its peers. For information on how to trade XOMA Stock refer to our How to Trade XOMA Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XOMA Corp. Anticipated expansion of XOMA directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive XOMA Corp assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.48) | Earnings Share 0.72 | Revenue Per Share | Quarterly Revenue Growth 0.299 | Return On Assets |
XOMA Corp's market price often diverges from its book value, the accounting figure shown on XOMA's balance sheet. Smart investors calculate XOMA Corp's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since XOMA Corp's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between XOMA Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if XOMA Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XOMA Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.